the semaglutide thing finally clicked for me and I want to write it down
the semaglutide thing finally clicked for me and I want to write it down. I have gone back and forth on this for months.
Delayed gastric emptying is most pronounced early and attenuates with continued dosing, which is why the constipation usually fades at a stable dose.
Steady state after a dose change takes four to five half-lives, so the fair judgement point on a new step is about a month, not four days.
Research-use-only material is not approved for human use, so anything in this thread about how a compounded or research vial "should" behave is a chemistry discussion, not a dosing one.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
The escalation schedule in the trials existed to keep people on the drug. It is a tolerability ramp, and it is why the label reads the way it does.
STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.
Disagree. 2.4 is the top of the label, not the goal, and "everyone ends up there" is just survivorship in the posts you read.
Retitled to match the body. The original promised a comparison the post does not make.
nausea that arrives on day two and fades by day four is the standard shape
protein first, then everything else gets easier
Kept a log from week one and the single most useful column turned out to be waist, not weight.
First month I lost almost nothing and nearly quit. Month two and three were where it all happened.
Correct, and worth adding: the trial average is an average. Half the people in it did worse than 15% and were still on the drug.
dose day drift of a day either way is fine, the curve barely notices